Effect of sodium-glucose co-transporter-2 inhibitors on impaired ventricular repolarization in people with Type 2 diabetes

Diabetic Medicine

Volumn 34, Issue 10, 2017, Pages 1367-1371

  Sato, T ^a   Miki, T ^a   Ohnishi, H ^b   Yamashita, T ^a   Takada, A ^c   Yano, T ^a   Tanno, M ^a   Tsuchida, A ^d   Miura, T ^a  

^a Renal and Metabolic Medicine ^*  (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Steel Memorial Muroran Hospital   (Japan)

^d Sapporo General Hospital of Hokkaido Railway Company   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; CANAGLIFLOZIN; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOFOGLIFLOZIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ADULT; ARTICLE; BODY WEIGHT; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DIABETIC COMPLICATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISPERSION; FEMALE; GLYCEMIC CONTROL; HEART RATE; HEART REPOLARIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; QTC INTERVAL; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; AGED; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETIC ANGIOPATHY; DRUG EFFECT; ETIOLOGY; HEART VENTRICLE FUNCTION; TREATMENT OUTCOME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION;

EID: 85026780953     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.13424     Document Type: Article

References (20)

1. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus- mechanisms, management, and clinical considerations. Circulation 2016; 133: 2459–2502.
2. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016; 59: 1333–1339.
3. Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci 2013; 1281: 36–50.
4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117–2128.
5. Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36: 1749–1766.
6. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest 2004; 27: 175–181.
7. Prenner SB, Shah SJ, Goldberger JJ, Sauer AJ. Repolarization heterogeneity: beyond the QT interval. J Am Heart Assoc 2016; 5: e003607.
8. Castro-Torres Y, Carmona-Puerta R, Katholi RE. Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice. World J Clin Cases 2015; 3: 705–720.
9. Miki T, Tobisawa T, Sato T, Tanno M, Yano T, Akasaka H et al. Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes? Cardiovasc Diabetol 2014; 13: 125.
10. Klimas J, Kruzliak P, Rabkin SW. Modulation of the QT interval duration in hypertension with antihypertensive treatment. Hypertens Res 2015; 38: 447–454.
11. Omran J, Firwana B, Koerber S, Bostick B, Alpert MA. Effect of obesity and weight loss on ventricular repolarization: a systematic review and meta-analysis. Obes Rev 2016; 17: 520–530.
12. Elming H, Holm E, Jun L, Torp-Pedersen C, Køber L, Kircshoff M et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 1998; 19: 1391–1400.
13. Ring A, Brand T, Macha S, Breithaupt-Groegler K, Simons G, Walter B et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol 2013; 12: 70.
14. Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A et al. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 2016; 39: e212–213.
15. 2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem 2015; 400: 57–68.
16. + exchanger in rats and rabbits. Diabetologia 2017; 60: 568–573.
17. + channel effect. Am J Cardiol 2002; 90: 1103–1106.
18. Ferrannini E, Galvan AQ, Gastaldelli A, Camastra S, Sironi AM, Toschi E et al. Insulin: new roles for an ancient hormone. Eur J Clin Invest 1999; 29: 842–852.
19. Rana BS, Lim PO, Naas AA, Ogston SA, Newton RW, Jung RT et al. QT interval abnormalities are often present at diagnosis in diabetes and are better predictors of cardiac death than ankle brachial pressure index and autonomic function tests. Heart 2005; 91: 44–50.
20. Cuddy TE, Halli PS, Tate RB. QT dispersion and heart rate predict the risk of sudden unexpected cardiac death in men: the Manitoba Follow-Up Study. Prev Cardiol 2009; 12: 27–33.